Serotonin pp 359-368 | Cite as

Structure-Activity Relationships in the Actions of 1-Phenyl-Piperazines on Brain Serotonin Receptors

  • Ray W. Fuller
  • Norman R. Mason
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 133)


Several compounds containing a 1-phenyl-piperazine moiety have been reported to interact with central serotoninergic systems. For example, trazodone, 2-(3-[4-(m-chlorophenyl)-1piperazinyl]propyl)-S-triazolo-[4,3-a]pyridin-3[2H]-one (Fig. 1), has been variously described as a serotonin uptake inhibitor, agonist, and antagonist (Silvestrini et al, 1968; Garattini et al, 1976; Maj et al, 1979). Mepiprazole, 1-(m-chlorophenyl)-4[2-(5-methyl-3-pyrazolyl)-ethyl]-piperazine (Fig. 1), has been claimed to increase serotonin concentration at the receptor site by a combination of neuronal uptake inhibition and release (Placheta et al, 1975), and Fuxe et al (1976) have suggested that mepiprazole causes extragranular release of serotonin stores. Related compounds with a simpler structure have also been studied. For example, 1-(m-chlorophenyl)-piperazine, a possible metabolite of trazodone (and of mepiprazole), was observed to inhibit serotonin uptake more potently than trazodone (Garattini et al, 1976). l-(m-Trifluoromethylphenyl)-piperazine has been reported to have serotonin agonist activity (Fuller et al, 1978; Fuller and Clemens, 1979). Quipazine and MK-212 are serotonin agonists (Rodriguez et al, 1973; Clineschmidt et al, 1977) that are 1-aryl-piperazines but not 1-phenyl-piperazines (see Fig. 1). Because of these reports, we have undertaken a study of various substituted 1-phenyl-piperazines and related compounds to determine their ability to act directly on serotonin receptors as indicated by their competition with 3H-serotonin for binding to membranes from rat brain in vitro. These effects and others of some 1-phenyl-piperazines are described herein.


Methyl Orange Serotonin Receptor Serotonin Uptake Serum Corticosterone Prolactin Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Axelrod, J., 1954, Studies on sympathomimetic amines. II. The biotransformation and physiological disposition of d-amphetamine, d-p-hydroxyamphetamine and d-methamphetamine, J. Pharmacol. Exp. Ther., 110: 315.Google Scholar
  2. Bennett, J. P., Jr., and Snyder, S. H., 1976, Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors, Mol. Pharmacol., 12: 373.Google Scholar
  3. Clineschmidt, B. V., McGuffin, J. C., and Pflueger, A. B., 1977, Central serotonin-like activity of 6-chloro-2[l-piperazinyl]-pyrazine (CPP: MK-212), Eur. J. Pharmacol., 44: 65.Google Scholar
  4. Clineschmidt, B. V., Totaro, J. A., Pflueger, A. B., and McGuffin, J. C., 1978, Inhibition of the serotoninergic uptake system by MK-212 (6-chloro-2-[1-piperazinyl]pyrazine), Pharmacol. Res. Commun., 10: 219.Google Scholar
  5. Fuller, R. W., and Clemens, J. A., 1979, 1-(m-Trifluoromethylphenyl)-piperazine, a serotonin agonist, increases serum corticosterone and prolactin concentration in rats, IRCS Med. Sci., 7: 106.Google Scholar
  6. Fuller, R. W., Snoddy, H. D., Mason, N. R., and Molloy, B. B., 1978, Effect of 1-(m-trifluoromethylphenyl)-piperazine on 3H-serotonin binding to membranes from rat brain in vitro and on serotonin turnover in rat brain in vivo, Eur. J. Pharmacol., 52: 11.Google Scholar
  7. Fuller, R. W., Snoddy, H. D., Perry, K. W., Roush, B. W., Molloy, B. B., Bymaster, F. P., and Wong, D. T., 1976, The effects of quipazine on serotonin metabolism in rat brain, Life Sci., 18: 925.PubMedCrossRefGoogle Scholar
  8. Fuller, R. W., and Steinberg, M., 1976, Regulation of enzymes that synthesize neurotransmitter monoamines, Adv. Enz. Regul., 14: 347.Google Scholar
  9. Fuxe, K., Agnati, L. F., and Ungerstedt, U., 1976, The effect of mepiprazole on central monoamine neurons. Evidence for increased 5-hydroxytryptamine and dopamine receptor activity, Eur. J. Pharmacol., 35: 93.Google Scholar
  10. Garattini, S., de Gaetano, G., Samanin, R., Bernasconi, S., and Roncaglioni, M. C., 1976, Effects of trazodone on serotonin in the brain and platelets of the rat, Biochem. Pharmacol., 25: 13.Google Scholar
  11. Hamon, M., Bourgoin, S., Enjalbert, A., Bockaert, J., Hery, F., Ternaux, J. P., and Glowinski, J., 1976, The effects of quipazine on 5-HT metabolism in the rat brain, Naunyn-Schmiedeberg’s Arch. Pharmacol., 294: 99.Google Scholar
  12. Maj, J., Palider, W., and Rawlow, A., 1979, Trazodone, a central serotonin antagonist and agonist, J. Neural Transmission, 44: 237.CrossRefGoogle Scholar
  13. Miller, F. P., Cox, R. H., Jr., Snodgrass, W. R., and Maickel, R. P., 1970, Comparative effects of p-chlorophenylalanine, p-chloroamphetamine and p-chloro-N-methylamphet- amine on rat brain norepinephrine, serotonin and 5hydroxyindole-3-acetic acid, Biochem. Pharmacol., 19: 435.Google Scholar
  14. Placheta, P., Singer, E., Kriwanek, W., and Hertting, G., 1976, Mepiprazole, a new psychotropic drug: effects on uptake and retention of monoamines in rat brain synaptosomes, Psychopharmacol., 48: 295.CrossRefGoogle Scholar
  15. Rodriguez, R., Rojas-Ramirez, J. A., and Drucker-Colin, R. R., 1973, Serotonin-like actions of quipazine on the central nervous system, Eur. J. Pharmacol., 24: 164.Google Scholar
  16. Silvestrini, B., Cioli, V., Burberi, S., and Catanese, B., 1968, Pharmacological properties of AF 1161, a new psychotropic drug, Int. J. Neuropharmacol., 7: 587.Google Scholar
  17. Solem, J. H., and Brinck-Johnsen, T., 1965, An evaluation of a method for determination of free corticosteroids in minute quantities of mouse plasma, Scand. J. Clin. Lab. Invest. Suppl. 80, 17: 1.Google Scholar
  18. Whitaker, P. M., and Seeman, P., 1978, High-affinity 3Hserotonin binding to caudate: inhibition by hallucinogens and serotoninergic drugs, Psychopharmacol., 59: 1.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • Ray W. Fuller
    • 1
  • Norman R. Mason
    • 1
  1. 1.The Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA

Personalised recommendations